Axsome settles Auvelity patent litigation with Teva
JHVEPhoto Axsome Therapeutics (NASDAQ:AXSM) stock rallied 15% in morning trading on news it has settled
JHVEPhoto Axsome Therapeutics (NASDAQ:AXSM) stock rallied 15% in morning trading on news it has settled
JHVEPhoto/iStock Editorial via Getty Images The pivotal clinical phase 3 trial for the olanzapine Long-Acting
Teva Pharmaceutical (NYSE:TEVA) may offer a variety of securities, including American Depositary Shares (ADSs), debt
JHVEPhoto Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed
krblokhin/iStock Editorial via Getty Images Trade groups representing companies in the pharmaceutical distributor and generic/biosimilar
Jonathan Kitchen Stock futures exhibited mixed performance on Wednesday as investors awaited earnings from major
*Other Operating Data Consensus Source: Bloomberg More on Teva Pharmaceutical Industries Limited: Teva Pharmaceutical Non-GAAP
JHVEPhoto/iStock Editorial via Getty Images Teva Pharmaceutical (NYSE:TEVA) lost ~5% in the premarket even after
Teva Pharmaceutical press release (NYSE:TEVA): Q4 Non-GAAP EPS of $0.71 beats by $0.01. Revenue of
Teva Pharmaceutical (NYSE:TEVA) is scheduled to announce Q4 earnings results on Wednesday, January 29th, before